Company release, inside information,
THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
The goal of the planned collaboration is to increase the probability of success for enhanced BBB (Blood-Brain-Barrier) penetration in the nasal drug delivery route for CDNF and x-CDNF. The collaboration between Herantis and Nanoform is based on a letter of intent regarding collaboration. The parties intend to enter into a binding collaboration agreement based on the letter of intent.
Under the letter of intent, Nanoform will subscribe for shares in Herantis, subject to certain customary conditions, for an aggregate amount of
Subject to negotiating and finalizing a binding collaboration agreement, Nanoform will in the partnership undertake, for compensation on standard commercial terms, two proof of concept studies on Herantis' CDNF and xCDNF molecules leveraging Nanoform's novel platform and its in-house formulation expertise.
"The intended partnership with Nanoform is a great opportunity for Herantis and further confirms Herantis' unique capabilities and potential in the development of our CDNF program. Nanoform technology shows promise for enhanced drug delivery applications in this highly complex and challenging field and we look forward to working together. Our aim is that this will open up new possibilities for improving the lives of patients with Parkinson's and other related diseases. We value the opportunity to enter into collaboration with Nanoform and look forward to what the future brings between both companies." said
For more information, please contact:
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
---------------------------------
Certified Advisor:
Company website: www.herantis.com
About
Forward-looking statements
This company release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis' future financial position and results of operations, the company's strategy, objectives, future developments in the markets in which the company participates or is seeking to participate or anticipated regulatory changes in the markets in which the company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should" or "will" or the negative of such terms or other comparable terminology.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The company's actual results of operations, including the company's financial condition and liquidity and the development of the industry in which the company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis' strategy, risks and uncertainties associated with the development and/or approval of Herantis' drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis' potential market and industry, Herantis' freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors' patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors.
In addition, even if Herantis' historical results of operations, including the company's financial condition and liquidity and the development of the industry in which the company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.
Important notice
The distribution of this release may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restrictions. The information contained herein is not for publication or distribution, directly or indirectly, in or into
This release does not constitute a prospectus as defined in the Prospectus Regulation ((EU) 2017/1129) and as such, does not constitute or form part of and should not be construed as, an offer to sell, or the solicitation or invitation of any offer to buy, acquire or subscribe for, any securities or an inducement to enter into investment activity.
This release is directed only to (A) persons who are outside
This release does not constitute an offer for sale of securities in
https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-and-nanoform-sign-a-letter-of-intent--loi--for-collaboration,c3257551
https://mb.cision.com/Main/18884/3257551/1350430.pdf
(c) 2020 Cision. All rights reserved., source